These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Development of agonists/antagonists for protease-activated receptors (PARs) and the possible therapeutic application to gastrointestinal diseases]. Sekiguchi F Yakugaku Zasshi; 2005 Jun; 125(6):491-8. PubMed ID: 15930817 [TBL] [Abstract][Full Text] [Related]
3. Proteinases, proteinase-activated receptors (PARs) and the pathophysiology of cancer and diseases of the cardiovascular, musculoskeletal, nervous and gastrointestinal systems. Hansen KK; Oikonomopoulou K; Li Y; Hollenberg MD Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):377-92. PubMed ID: 17952408 [TBL] [Abstract][Full Text] [Related]
4. Challenges and Opportunities in Protease-Activated Receptor Drug Development. Hamilton JR; Trejo J Annu Rev Pharmacol Toxicol; 2017 Jan; 57():349-373. PubMed ID: 27618736 [TBL] [Abstract][Full Text] [Related]
9. Differential signaling by protease-activated receptors: implications for therapeutic targeting. Sidhu TS; French SL; Hamilton JR Int J Mol Sci; 2014 Apr; 15(4):6169-83. PubMed ID: 24733067 [TBL] [Abstract][Full Text] [Related]
10. Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. Ramachandran R; Hollenberg MD Br J Pharmacol; 2008 Mar; 153 Suppl 1(Suppl 1):S263-82. PubMed ID: 18059329 [TBL] [Abstract][Full Text] [Related]
11. Recent advances in synthesis of PAR ligands as therapeutic strategy for inflammatory diseases. Severino B; Santagada V; Perissutti E; Fiorino F; Frecentese F; De Angelis F; Esposito A; Caliendo G Mini Rev Med Chem; 2009 Jun; 9(6):653-63. PubMed ID: 19519491 [TBL] [Abstract][Full Text] [Related]
12. Agonists and antagonists of protease activated receptors (PARs). Barry GD; Le GT; Fairlie DP Curr Med Chem; 2006; 13(3):243-65. PubMed ID: 16475935 [TBL] [Abstract][Full Text] [Related]
13. Physiology, pharmacology, and therapeutic potential of protease-activated receptors in vascular disease. Lee H; Hamilton JR Pharmacol Ther; 2012 May; 134(2):246-59. PubMed ID: 22327235 [TBL] [Abstract][Full Text] [Related]
18. Progress in the understanding of protease-activated receptors. Gabazza EC; Taguchi O; Kamada H; Hayashi T; Adachi Y; Suzuki K Int J Hematol; 2004 Feb; 79(2):117-22. PubMed ID: 15005337 [TBL] [Abstract][Full Text] [Related]
19. Protease-activated receptors (PARs) are partly pro-inflammatory and partly anti-inflammatory: will PAR agonists or antagonists participate in future drug therapies? De Campo BA; Henry PJ Curr Drug Targets; 2006 May; 7(5):629-37. PubMed ID: 16719772 [TBL] [Abstract][Full Text] [Related]
20. International Union of Pharmacology. XXVIII. Proteinase-activated receptors. Hollenberg MD; Compton SJ Pharmacol Rev; 2002 Jun; 54(2):203-17. PubMed ID: 12037136 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]